Metastatic Melanoma
Metastatic melanoma is a type of skin cancer that has spread from the original site to other parts of the body, making it more challenging to treat. It can occur in various organs and often requires aggressive treatment.
Melanoma Treatment: Nivolumab + Relatlimab Injection Study
We are comparing a new way to give a combination treatment for advanced melanoma to see if it works as well as the traditional method. This study is for people who have not yet been treated for their melanoma.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 12 and 75 years old and weigh at least 40 kg?
- Do you have confirmed Stage III or Stage IV melanoma (cancer that cannot be removed or has spread)?
- Are you currently pregnant or breastfeeding?
- Do you have any known autoimmune diseases, except for Type I diabetes or hypothyroidism that only needs hormone replacement?
- Have you received any cancer treatment in the last 2 years, except for certain skin cancers?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Nivolumab
Relatlimab
rHuPH20
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Noe LGA Gesundheit Region Mitte GmbH
University Hospital St. Poelten, Department of Dermatology
Sankt Pölten, Austria
Medical University Of Vienna
Department of Dermatology
Vienna, Austria
Grand Hopital De Charleroi
Oncology
Gilly, Belgium
Sponsor: Bristol-Myers Squibb International Corporation
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.